Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nektar Therapeutics - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NKTR
Nasdaq
8731
https://www.nektar.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nektar Therapeutics
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Mar 22nd, 2024 6:00 pm
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
- Mar 6th, 2024 5:33 pm
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
- Mar 5th, 2024 3:07 pm
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
- Mar 5th, 2024 2:13 pm
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
- Mar 5th, 2024 2:00 pm
Q4 2023 Nektar Therapeutics Earnings Call
- Mar 5th, 2024 12:19 pm
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
- Mar 4th, 2024 10:30 pm
Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results
- Mar 4th, 2024 9:51 pm
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
- Mar 4th, 2024 9:15 pm
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
- Mar 4th, 2024 1:30 pm
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
- Feb 27th, 2024 11:00 pm
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
- Feb 26th, 2024 11:00 pm
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
- Feb 20th, 2024 3:00 pm
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
- Feb 16th, 2024 1:45 pm
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
- Jan 9th, 2024 2:25 pm
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
- Jan 3rd, 2024 11:00 pm
Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR) institutional owners
- Dec 30th, 2023 12:38 pm
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
- Dec 11th, 2023 11:00 pm
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
- Dec 8th, 2023 4:30 pm
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
- Dec 7th, 2023 4:31 pm
Scroll